Nerinetide is in clinical development for the treatment of acute ischaemic stroke. Ischaemic stroke is the most common type of stroke. It happens when a blood vessel is blocked by a blood clot, cutting off blood flow to part of the brain (ischaemia). Without blood supply, brain cells can be damaged or destroyed because they may not receive enough oxygen. Symptoms may include numbness or weakness on one side of the body and problems with balance, speech and swallowing. Symptoms may range from mild and resolve, through severe strokes that can lead to long-term disability, coma and death. Early treatment is critical to improve outcomes and aims to restore blood flow to the brain, prevent and possibly repair the damage. Current therapies address only the restoration of blood flow, but not protection of the brain by enhancing its resilience to ischaemia.
Nerinetide is an innovative new drug that protects the brain during an acute ischaemic stroke. As a neuroprotectant, nerinetide does not dissolve blood clots, but effectively pauses the toxic chemical reactions triggered by stroke. Treatment with nerinetide is being positioned to be initiated as soon as possible after the onset of symptoms. If licensed, nerinetide would provide critical time to patients with a stroke by stopping the loss of brain cells until further treatment can be administered.
Lacosamide is a medicinal product that is being developed for the treatment of Primary Generalised Tonic-Clonic Seizures (PGTCS). Epilepsy is a neurological disorder that is characterised by an imbalance in the excitation and inhibition of the brain and this imbalance causes a phenomenon known as a seizure. Seizures are brief increases in electrical activity within …